Norrie Disease

Norrie disease is a rare genetic condition that primarily affects boys and causes severe vision loss at birth or shortly after. It happens because of a change (mutation) in a specific gene that is needed for the eyes and ears to develop properly. In babies with Norrie disease, the retina—the part of the eye that senses light—does not form correctly and detaches from the back of the eye. This leads to blindness and can cause the eyes to look cloudy or white in the center. Over time, the eyes may shrink and develop cataracts. In addition to vision loss, most people with Norrie disease will also develop hearing loss. This usually starts during childhood or the teenage years and gets worse over time, often requiring hearing aids or other supportive devices. Some children with the condition may also have delays in their development, learning difficulties, or behavioral challenges. Because the disease affects multiple parts of the body, it requires care from a team of different doctors. While there is currently no cure for Norrie disease, treatments focus on managing the symptoms and supporting the child's development. Eye surgeries may be done early on to help preserve the shape of the eye or relieve pressure, even if they cannot restore vision. Hearing aids and special education programs are very important to help children communicate and reach their full potential. Genetic counseling is also recommended for families to understand how the condition is passed down and what it means for future pregnancies.

Condition category: Syndromic IRD

Prevalence: Less than 1 in 1,000,000

Inheritance patterns: X-Linked Recessive

Age of onset: Birth to early childhood

Clinical overview: Norrie disease is a rare, severe X-linked recessive genetic disorder primarily characterized by congenital or early infantile blindness. It is the most severe phenotype within the spectrum of NDP-related retinopathies. The disease is caused by mutations in the NDP gene, which leads to abnormal development of the retina (retinal dysgenesis). This abnormal development results in the formation of a fibrovascular mass behind the lens, often referred to as a pseudoglioma, and subsequent retinal detachment. The ocular findings are typically bilateral and symmetric, leading to profound and irreversible vision loss very early in life. Beyond the ocular manifestations, Norrie disease is a multisystem disorder. A significant majority of affected males (up to 90%) develop progressive sensorineural hearing loss, typically beginning in the second decade of life. Additionally, approximately 30% to 50% of patients experience varying degrees of cognitive impairment, developmental delays, or behavioral and psychiatric issues, such as psychosis or autism-like features. Some individuals may also present with peripheral vascular disease or other systemic abnormalities. The clinical significance of Norrie disease lies in its profound impact on sensory function and overall development. The combination of early-onset blindness and later-onset deafness (dual sensory impairment) presents substantial challenges for communication, education, and independent living. Early diagnosis is crucial for implementing supportive therapies, monitoring for extraocular symptoms, and providing genetic counseling to affected families. The condition is cataloged under OMIM #310600 (Norrie disease) and OMIM #300658 (NDP gene), and its Orphanet number is ORPHA:649.

Patient and family guide: Norrie disease is a rare genetic condition that primarily affects boys and causes severe vision loss at birth or shortly after. It happens because of a change (mutation) in a specific gene that is needed for the eyes and ears to develop properly. In babies with Norrie disease, the retina—the part of the eye that senses light—does not form correctly and detaches from the back of the eye. This leads to blindness and can cause the eyes to look cloudy or white in the center. Over time, the eyes may shrink and develop cataracts. In addition to vision loss, most people with Norrie disease will also develop hearing loss. This usually starts during childhood or the teenage years and gets worse over time, often requiring hearing aids or other supportive devices. Some children with the condition may also have delays in their development, learning difficulties, or behavioral challenges. Because the disease affects multiple parts of the body, it requires care from a team of different doctors. While there is currently no cure for Norrie disease, treatments focus on managing the symptoms and supporting the child's development. Eye surgeries may be done early on to help preserve the shape of the eye or relieve pressure, even if they cannot restore vision. Hearing aids and special education programs are very important to help children communicate and reach their full potential. Genetic counseling is also recommended for families to understand how the condition is passed down and what it means for future pregnancies.

Symptoms and clinical features: The clinical presentation of Norrie disease is characterized by a progression of severe ocular and systemic symptoms. In the early stage, typically at birth or within the first few months of life, the primary symptom is profound visual impairment. Parents or pediatricians may notice leukocoria (a white reflection in the pupil) or microphthalmia (abnormally small eyes). Examination reveals a grayish-yellow fibrovascular mass behind the lens (pseudoglioma) and partial or complete retinal detachment. The anterior segment of the eye may initially appear normal, but the profound lack of vision is evident early on. During the intermediate stage, which spans childhood, the ocular disease progresses to more severe degenerative changes. The eyes may develop cataracts, iris atrophy, and synechiae (adhesions between the iris and the lens or cornea). The anterior chamber may become shallow, and patients are at risk of developing increased intraocular pressure, which can be painful. It is also during this stage, typically in the second decade of life (median age 12 years), that the onset of sensorineural hearing loss usually occurs. The hearing loss is initially mild but progressive. Additionally, developmental delays, cognitive impairment, or behavioral issues may become more apparent during childhood. In the advanced stage, which extends into late adolescence and adulthood, the ocular degeneration often culminates in phthisis bulbi, where the eyes become shrunken, opaque, and completely non-functional. The sensorineural hearing loss continues to progress, often resulting in severe to profound deafness by the third or fourth decade, leading to dual sensory impairment. Cognitive and behavioral issues, if present, persist and may include psychotic features or significant intellectual disability. Some patients may also develop peripheral vascular disease, such as venous stasis ulcers, as part of the advanced systemic manifestations of the disease.

Molecular pathology: Norrie disease is caused by mutations in the NDP gene, which encodes a 133-amino acid secreted protein called norrin. Norrin is a cystine-knot growth factor that plays a crucial role in the Wnt/beta-catenin signaling pathway. It acts as a high-affinity ligand for the Frizzled-4 (FZD4) receptor, working in conjunction with the coreceptor LRP5 and the auxiliary protein TSPAN12. This signaling cascade is essential for the normal development and maintenance of the vascular systems in the retina and the stria vascularis of the inner ear. During embryonic development, norrin signaling is critical for the specialization of retinal cells, particularly Müller glia, and for the angiogenesis that establishes the retinal blood supply. Mutations in the NDP gene lead to a defective or absent norrin protein, which fails to bind to the FZD4 receptor and initiate the Wnt signaling cascade. This disruption results in severe retinal dysgenesis, characterized by a failure of the retinal vasculature to develop properly and an accumulation of immature, undifferentiated retinal cells. The lack of proper vascularization and cellular differentiation leads to the formation of a fibrovascular mass behind the lens (pseudoglioma) and subsequent retinal detachment. In the inner ear, defective norrin signaling impairs the vascularization of the stria vascularis, leading to the progressive degeneration of cochlear hair cells and resulting in sensorineural hearing loss. The pleiotropic effects of norrin deficiency also explain the potential for cognitive impairment and peripheral vascular issues seen in some patients, as norrin is expressed in the brain and other tissues.

Genetics: Norrie disease is inherited in an X-linked recessive pattern. It is caused by pathogenic variants in the NDP (Norrie Disease Pseudoglioma) gene, located on the X chromosome at locus Xp11.3. Because males have only one X chromosome, a single mutated copy of the NDP gene is sufficient to cause the disease. Females, having two X chromosomes, are typically asymptomatic carriers if they inherit one mutated copy, as the normal allele compensates. However, rare manifesting female carriers can exhibit mild features, such as retinal abnormalities or partial hearing loss, due to skewed X-chromosome inactivation. The NDP gene is the only known causative gene for Norrie disease. Over 75 different pathogenic variants have been identified, including missense, nonsense, splice site mutations, and partial or whole gene deletions. These mutations disrupt the production or function of the norrin protein. The disease exhibits complete penetrance in affected males, meaning all males with a disease-causing mutation will show symptoms, though the severity can vary. There is significant genotype-phenotype correlation in Norrie disease. Nonsense mutations or large deletions that result in a complete loss of norrin protein function typically cause the classic, severe phenotype, which includes profound congenital blindness, progressive hearing loss, and a higher likelihood of cognitive impairment or systemic issues. In contrast, missense mutations that allow for some residual protein function may result in milder phenotypes, sometimes overlapping with other NDP-related retinopathies like X-linked familial exudative vitreoretinopathy (FEVR) or Coats disease. However, phenotypic variability can still exist among individuals with the same mutation, even within the same family.

Diagnostic evaluation: Clinical diagnosis of Norrie disease is primarily based on characteristic ocular findings observed at birth or in early infancy. Initial examination often reveals leukocoria (white pupillary reflex) or microphthalmia. Slit-lamp biomicroscopy may show a shallow anterior chamber, iris atrophy, cataracts, and synechiae. Fundoscopy typically demonstrates a grayish-yellow, glistening, elevated retrolental mass (pseudoglioma) consisting of immature retinal cells, along with partial or complete retinal detachment. These findings are characteristically bilateral and symmetric. Optical coherence tomography (OCT) and other advanced imaging modalities can help characterize the extent of retinal dysplasia and detachment, though their use may be limited by media opacities such as cataracts or severe retrolental masses. Electroretinography (ERG) typically shows severely reduced or absent responses due to the profound retinal dysplasia and detachment, reflecting the lack of functional photoreceptors and inner retinal cells. Molecular genetic testing is the definitive method for confirming the diagnosis. Sequence analysis of the NDP gene can identify pathogenic variants (missense, nonsense, or splice site mutations) in approximately 85% of affected males. For the remaining 15% of cases, deletion/duplication analysis is utilized to detect submicroscopic deletions. Linkage analysis may be employed when direct mutation detection is unavailable or uninformative in familial cases. The differential diagnosis includes other causes of leukocoria and early childhood blindness, such as retinoblastoma, persistent fetal vasculature (PFV), familial exudative vitreoretinopathy (FEVR), retinopathy of prematurity (ROP), and Coats disease. Retinoblastoma must be urgently ruled out due to its life-threatening nature. The bilateral, symmetric presentation and X-linked inheritance pattern, along with the eventual development of hearing loss and potential cognitive issues, help distinguish Norrie disease from these other entities.

Differential diagnosis: Differential diagnosis of Norrie disease includes: (1) Retinopathy of prematurity (stage 5) — history of prematurity; bilateral retinal detachment. (2) Familial exudative vitreoretinopathy — variable severity, no hearing loss or intellectual disability. (3) Persistent fetal vasculature — usually unilateral, microphthalmos. (4) Retinoblastoma — leukocoria, calcification on imaging, no hearing loss. (5) Coats disease — unilateral, exudative retinal detachment, male predominance. (6) Incontinentia pigmenti — X-linked dominant (lethal in males), skin lesions precede eye findings.

Natural history: The natural history of Norrie disease begins at birth or in the first few months of life with profound visual impairment. Infants typically present with leukocoria or microphthalmia due to the presence of a retrolental fibrovascular mass and retinal detachment. The ocular disease is progressive; the eyes often undergo further degenerative changes, including the development of cataracts, iris atrophy, and eventually phthisis bulbi (shrinkage of the eyeball), which is usually apparent by the end of the first decade of life. Vision loss is typically complete and irreversible from a very early age. Sensorineural hearing loss is a hallmark of the disease's progression, developing in approximately 85-90% of affected individuals. The onset of hearing loss typically occurs in the second decade of life, with a median age of onset around 12 years, though it can range from early childhood to adulthood. The hearing loss is progressive, often starting as mild and advancing to severe or profound deafness by the third or fourth decade, significantly impacting communication and quality of life. Cognitive and developmental issues may also unfold over time. About 30-50% of patients experience developmental delays, intellectual disability, or behavioral problems, which can include autism-like features or psychosis. These neurological symptoms can become more apparent as the child grows. In cases with large contiguous gene deletions involving the NDP gene and adjacent regions (such as the MAOA and MAOB genes), patients may exhibit more severe neurological phenotypes, including severe intellectual disability, seizures, and complex behavioral disorders.

Management and treatment research: Currently, there is no cure for Norrie disease, and treatment is primarily supportive and symptom-directed, requiring a multidisciplinary approach. For the ocular manifestations, early surgical intervention may be considered, although it cannot restore vision. Procedures such as laser photocoagulation, vitrectomy, or lensectomy may be performed in the early stages to manage retinal detachment, remove cataracts, or prevent complications like painful glaucoma and phthisis bulbi. The goal of these interventions is often to preserve the structural integrity of the globe and alleviate pain rather than to improve visual acuity, which is typically profoundly and irreversibly affected from birth. Management of the extraocular symptoms is a critical component of care. For the progressive sensorineural hearing loss, regular audiological monitoring is essential. Hearing aids are often beneficial in the early to intermediate stages of hearing loss. As the deafness progresses to a severe or profound level, cochlear implantation has been shown to be highly effective in restoring functional hearing and improving communication. For patients with cognitive impairment, developmental delays, or behavioral issues, early intervention programs, special education, and psychiatric or behavioral therapies are necessary to maximize the individual's potential and quality of life. Research into emerging therapies is ongoing, particularly in the realm of gene therapy. Preclinical studies using adeno-associated virus (AAV)-mediated gene augmentation therapy in mouse models of Norrie disease have shown promise in rescuing retinal vascular development and preserving hearing function. However, these therapies are still in the experimental stages and have not yet reached clinical trials for human patients. Supportive care remains the cornerstone of management, encompassing visual and auditory rehabilitation, occupational therapy, and genetic counseling for affected families to understand the inheritance pattern and risks for future pregnancies.

Outlook: The prognosis for visual outcomes in Norrie disease is very poor, as the condition typically results in profound, irreversible blindness at birth or within the first few months of life. The progressive nature of the ocular degeneration often leads to phthisis bulbi (shrinkage of the eye) and cataracts. The development of progressive sensorineural hearing loss, usually beginning in the second decade, further complicates the clinical picture, leading to dual sensory impairment (deafblindness) in many patients. Quality of life is significantly impacted by the combination of vision and hearing loss, requiring extensive special education, adaptive training, and supportive care. The presence and severity of cognitive impairment, developmental delays, or behavioral issues (seen in 30-50% of patients) are major factors that further influence the long-term prognosis and the level of independence an individual can achieve. While life expectancy is generally normal, the complex multisystem nature of the disease necessitates lifelong multidisciplinary medical management and robust psychosocial support for both the patient and their family.

Epidemiology: Norrie disease is an extremely rare genetic disorder, with an estimated prevalence of less than 1 in 1,000,000 individuals. More than 400 cases have been reported in the medical literature worldwide. As an X-linked recessive condition, it almost exclusively affects males, while females are typically asymptomatic carriers, though rare cases of manifesting female carriers with mild ocular or auditory symptoms have been documented due to skewed X-chromosome inactivation. The disease does not appear to have a specific geographic or ethnic predilection and has been reported in various populations, including individuals of European, African, Hispanic, and Asian descent. However, many of the initially described cases were of Scandinavian origin, particularly from Denmark, where the disease was first extensively characterized.

Selected references: 1. Warburg M. Norrie's disease: a new hereditary bilateral pseudotumour of the retina. Acta Ophthalmol (Copenh). 1961;39:757-772. PMID: 14005020 2. Scruggs BA, Reding MQ, Schimmenti LA. NDP-Related Retinopathies. 1999 Jul 30 [updated 2023 Mar 23]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. PMID: 20301506 3. Smith SE, Mullen TE, Graham D, Sims KB, Rehm HL. Norrie disease: extraocular clinical manifestations in 56 patients. Am J Med Genet A. 2012;158A(8):1909-1917. PMID: 22786811 4. Xu Q, Wang Y, Dabdoub A, et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004;116(6):883-895. PMID: 15035989 5. Berger W, van de Pol D, Warburg M, et al. Mutations in the candidate gene for Norrie disease. Hum Mol Genet. 1992;1(7):461-465. PMID: 1307245 6. Wang Z, Liu CH, Huang S, Chen J. Wnt Signaling in vascular eye diseases. Prog Retin Eye Res. 2019;70:110-133. PMID: 30503784